Composite maternal MACE events
| Variable | Composite MACE event (n=6) Mean±SEM or frequency (%) | No composite MACE event (n=26) Mean±SEM or frequency (%) | P value |
| Demographics | |||
| BMI | 30±5 | 34±9 | 0.10 |
| Age | 29±9 | 29±6 | 0.90 |
| ICM | 0 (0) | 3 (12) | 0.28 |
| PPCM | 2 (33) | 8 (31) | 0.28 |
| NICM | 4 (67) | 15 (57) | 0.28 |
| Comorbid illness | |||
| Hypertension | 2 (33) | 16 (62) | 0.21 |
| Diabetes | 3 (50) | 6 (23) | 0.21 |
| CAD | 0 (0) | 2 (8) | 0.35 |
| CKD | 0 (0) | 1 (4) | 0.52 |
| Obesity | 4 (67) | 16 (62) | 0.81 |
| Heart function | |||
| NYHA FC>2 | 4 (67) | 8 (33) | 0.30 |
| LVEF (%) | 35±11 | 43±12 | 0.22 |
| Cardiac medications (pre-pregnancy) | |||
| Beta-blocker | 6 (100) | 16 (62) | <0.05 |
| Angiotensin inhibitor | 4 (67) | 13 (50) | 0.46 |
| Aldosterone antagonist | 1 (17) | 4 (67) | 0.94 |
| Sacubitril/valsartan | 1 (17) | 1 (4) | 0.30 |
| Obstetric | |||
| Gestational diabetes | 2 (33) | 4 (15) | 0.34 |
| HDP | 1 (17) | 11 (42) | 0.45 |
| Estimated blood loss (mL) | 1058±231 | 482±111 | 0.03 |
| Spontaneous vaginal | 2 (33) | 9 (35) | 0.08 |
| Operative vaginal | 0 (0) | 9 (35) | 0.08 |
| Caesarean | 4 (67) | 8 (30) | 0.08 |
| Fetal | |||
| Birth weight (g) | 2813±283 | 2820±136 | 0.98 |
| APGAR 1 min | 8.2±0.9 | 7.1±0.4 | 0.26 |
| APGAR 5 min | 8.5±0.3 | 8.6±0.2 | 0.74 |
APGAR Score, Appearance, Pulse, Grimace, Activity and Respiration; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; HDP, hypertensive disorders of pregnancy; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; NICM, non-ICM; NYHA FC, New York Heart Association Functional Class; PPCM, peripartum CM; SEM, SE of the mean; VTE, venous thromboembolic events.